Accès gratuit
Numéro
Med Sci (Paris)
Volume 20, Numéro 11, Novembre 2004
Page(s) 973 - 978
Section M/S revues
DOI https://doi.org/10.1051/medsci/20042011973
Publié en ligne 15 novembre 2004
  1. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 1993; 366 : 575–80. [Google Scholar]
  2. De Luca F, Baron J. Molecular biology and clinical importance of the Ca2+-sensing receptor. Curr Opin Pediatr 1998; 10 : 435–40. [Google Scholar]
  3. Pearce S, Steinmann B. Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism. Clin Endocrinol 1999; 50 : 691–3. [Google Scholar]
  4. Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 2002; 8 : 2077–87. [Google Scholar]
  5. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95 : 4040–5. [Google Scholar]
  6. Ye C, Kanazirska M, Quinn S, et al. Modulation by polycationic Ca2+-sensing receptor agonists of nonselective cation channels in rat hippocampal neurons. Biochem Biophys Res Commun 1996; 224 : 271–80. [Google Scholar]
  7. Fox J, Lowe SH, Petty BA, Nemeth EF. NPS R-568 : a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999; 290 : 473–9. [Google Scholar]
  8. Heath H, Sanguinetti E, Oglesby S, Marriott T. Inhibition of parathyroid hormone secretion in vivo by NPS 5-568, a calcimimetic drug that targets the parathyroid cell-surface calcium receptor. Bone 1995; 16 : S85. [Google Scholar]
  9. Lalonde RL, Gaudreault J, Karhu DA, Marriott TB. Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther 1999; 65 : 40–9. [Google Scholar]
  10. Igarashi T, Ogata E, Maruyama K, Fukuda T. Effect of calcimimetic agent, KRN568, on gastrin secretion in healthy subjects. Endocrinol J 2000; 47 : 517–23. [Google Scholar]
  11. Silverberg SJ, Bone HG, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997; 337 : 1506–10. [Google Scholar]
  12. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88 : 5644–9. [Google Scholar]
  13. Collins MT, Skarulis MC, Bilezikian JP, et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998; 83 : 1083–8. [Google Scholar]
  14. Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 100 : 2977–83. [Google Scholar]
  15. Wada M, Ishii H, Furuya Y, et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 53 : 448–53. [Google Scholar]
  16. Wada M, Nagano N, Furuya Y, et al. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000; 57 : 50–8. [Google Scholar]
  17. Chin J, Miller SC, Wada M, et al. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 2000; 11 : 903–11. [Google Scholar]
  18. Fox J, Lowe SH, Conklin RL, Nemeth EF. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine 1999; 10 : 97–103. [Google Scholar]
  19. Ishii H, Wada M, Furuya Y, et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000; 26 : 175–82. [Google Scholar]
  20. Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 1998; 53 : 223–7. [Google Scholar]
  21. Akizawa T, Suzuki M, Tominaga Y, et al. Acute effect of calcimimetic agent (CA) on hemodialysis (HD) patients with secondary hyperparathyroidism (2HPT). J Am Soc Nephrol 1998; 9 : 561A. [Google Scholar]
  22. Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58 : 436–45. [Google Scholar]
  23. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13 : 1017–24. [Google Scholar]
  24. Coburn J, Barri Y, Turner S, et al. Single doses of the calcimimetic AMG-073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2000; 11 : 573A. [Google Scholar]
  25. Lindberg J, Moe S, Goodman W, et al. The calcimimetic AMG-073 reduces parathyroid hormone (PTH), phosphorus and calcium x phosphorus product in secondary hyperparathyroidism. J Am Soc Nephrol 2003; 63 : 248–54. [Google Scholar]
  26. Drueke T, Cunningham J, Goodman W, et al. Short-term treatment of secondary hyperparathyroidism (SHTP) with the calcimimetic agent AMG 073. J Am Soc Nephrol 2001; 12 : 764A. [Google Scholar]
  27. Quarles L, Spiegel D, Curzi M, et al. The effects of one-year treatment with the calcimimetic AMG-073 on bone health in ESRD patients with secondary hyperparathyroidism (SHPT). J Am Soc Nephrol 2002; 13 : 572A. [Google Scholar]
  28. Chertow G, Danese M, McCary L, Turner S. Self-reported cognitive functioning in hemodialysis patients with secondary HPT : the effect of the calcimimetic AMG-073. J Am Soc Nephrol 2002; 13 : 633A. [Google Scholar]
  29. Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350 : 1516–25. [Google Scholar]
  30. Gowen M, Stroup G, Dodds R, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000; 105 : 1595–604. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.